Topics

Lymphoma

Kite Pharma acknowledges patient death, says unrelated to cell therapy

Kite Pharma acknowledges patient death, says unrelated to cell therapy

Shares of Kite Pharma Inc. rebounded Monday after the company said the death of a clinical trial patient was unrelated to its promising blood cancer treatment. The Santa Monica company held a conference call with analysts to address "a high level of noise and misinformation recently in the market," Kite Chief Executive Arie S. Belldegrun said during the call. The company acknowledged that a cancer patient died during the trial of its KTE-C19 cell therapy, but said the death was found to be unrelated to the treatment for non-Hodgkin's lymphoma. "A clinical investigator of the study conducted an in-depth review of the death and concluded that this death was...

Loading
66°